In our lab, we develop novel imaging strategies to visualize specific molecular targets and biological events in cell and animal models. By integrating chemical and biological approaches, we aim to advance early diagnostic methods and develop therapeutic agents for major diseases. Our recent research focuses on the following areas:
1. Development of molecular imaging probes
We design and synthesize new fluorescent probes and radiotracers for the diagnosis of severe diseases such as Alzheimer’s disease and cancer. In addition, we develop enzyme-activatable nanoaggregation probes to image disease-associated enzymatic activity, and we validate their performance through in vivo animal imaging studies.
2. In vivo tracking of hazardous substances using molecular imaging techniques
We investigate the biodistribution and in vivo behavior of hazardous substances—including PHMG, CMIT/MIT, particulate matter, and microplastics—using radiolabeling strategies combined with nuclear imaging. This work enables quantitative evaluation of uptake, retention, and clearance in living organisms, supports assessment of physiological effects, and helps identify previously unrecognized toxicities.
3. Design and synthesis of new drug candidates
We synthesize natural product derivatives and synthetic drug candidates through diverse organic transformations. Recent projects include the development of anti-inflammatory agents based on chrysin derivatives and the synthesis of novel anti-tuberculosis candidates using isoniazid conjugates.